UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Autophagy as a therapeutic target in cancer

Cancer biology & therapy, 2011-01, Vol.11 (2), p.157-168

2011

Volltextzugriff (PDF)

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Breast cancer research : BCR, 2019-12, Vol.21 (1), p.143-143, Article 143

2019

Volltextzugriff (PDF)

Pembrolizumab for Early Triple-Negative Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (9), p.810-821

2020

Volltextzugriff (PDF)

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD5-03-PD5-03

2020

Volltextzugriff (PDF)

Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation

World journal of gastrointestinal oncology, 2014-03, Vol.6 (3), p.74-82

2014

Volltextzugriff (PDF)

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

Molecular & cellular oncology, 2015-07, Vol.2 (3), p.e975035-e975035

2015

Volltextzugriff (PDF)

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A364-A364

2021

Volltextzugriff (PDF)

The interplay between autophagy and ROS in tumorigenesis

Frontiers in oncology, 2012, Vol.2, p.171

2012

Volltextzugriff (PDF)

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Methods in Enzymology, 2008, Vol.446, p.61-76

2008

Volltextzugriff (PDF)

Role of autophagy in cancer

Nature reviews. Cancer, 2007-12, Vol.7 (12), p.961-967

2007

Volltextzugriff (PDF)

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Cancer research (Chicago, Ill.), 2020-12, Vol.80 (24), p.5427-5434

2020

Volltextzugriff (PDF)

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Clinical cancer research, 2021-06, Vol.27 (11), p.3061-3068

2021

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

The Lancet (British edition), 2021-07, Vol.398 (10294), p.24-25

2021

Volltextzugriff (PDF)

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.CT069-CT069

2017

Volltextzugriff (PDF)

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Breast cancer research and treatment, 2021-10, Vol.189 (3), p.653

2021

Volltextzugriff (PDF)

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

The New England journal of medicine, 2024-09

2024

Volltextzugriff (PDF)

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Future oncology (London, England), 2024-02, Vol.20 (6), p.335-348

2024

Volltextzugriff (PDF)

Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges

Journal of translational medicine, 2014-03, Vol.12 (1), p.79-79, Article 79

2014

Volltextzugriff (PDF)

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Journal of the National Comprehensive Cancer Network, 2020-08, Vol.18 (8), p.1096-1104

2020

Volltextzugriff (PDF)

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Methods in Enzymology, 2009, Vol.453, p.53-81

2009

Volltextzugriff (PDF)

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.OT-30-01-OT-30-01

2021

Volltextzugriff (PDF)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-01-PS12-01

2021

Volltextzugriff (PDF)

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Annals of oncology, 2022-07, Vol.33, p.S465

2022

Volltextzugriff (PDF)

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Volltextzugriff (PDF)

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT073-CT073

2020

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieJournal Of Clinical Oncology

ThemaAnimals

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Englisch
(58)
Japanisch
(1)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Autophagy as a therapeutic target in cancer

Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review

Pembrolizumab for Early Triple-Negative Breast Cancer

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation

p62: a hub of multiple signaling pathways in HER2-induced mammary tumorigenesis

338 Effects of pembrolizumab on the tumor microenvironment (TME) after one presurgery treatment cycle in patients with triple-negative breast cancer (TNBC): phase 1b KEYNOTE-173 study

The interplay between autophagy and ROS in tumorigenesis

Chapter 4 A Mouse Mammary Epithelial Cell Model to Identify Molecular Mechanisms Regulating Breast Cancer Progression

Role of autophagy in cancer

Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

Pembrolizumab plus chemotherapy in triple-negative breast cancer – Authors' reply

Abstract CT069: KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)

Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Time-restricted feeding and the realignment of biological rhythms: translational opportunities and challenges

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Chapter 4 Assessing Metabolic Stress and Autophagy Status in Epithelial Tumors

Abstract OT-30-01: KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

Abstract PS12-01: Pembrolizumab versus chemotherapy for previously treated metastatic triple-negative breast cancer (KEYNOTE-119): Efficacy in patients with lung or liver metastases

PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract CT073: IMPRIME 1 (NCT02981303): A novel phase 2 study in second-line +, metastatic triple negative breast cancer patients shows promising clinical benefit for the combination of the immune checkpoint inhibitor, pembrolizumab (pembro), with the novel innate immune activator, Imprime PGG

Aktive Filter

Suchergebnisse filtern